Bullish Case: Helium's +5.88% forecast plus the return surface's dense short-hold mass near 0% to modest gains implies mean-reversion support near $0.90, matching the 2024 base. Cash runway into 2028 and Roche/Genentech OpRegen milestones leave a cheap, de-risked optionality stub; a partner/progress PR could pop 30-60% off a washed-out price with 12/18 1.50-2.50C calls at modest premiums.

Bearish Case: LCTX broke below $1.00 on a -19.5% 60-day slide, the deepest regime in the return surface; its negative-tail mass and sub-year draws near -20% to -35% fit continued drift. Deep OTM put IVs of 375-500 price real binary/dilution risk, contango keeps convexity expensive, and the Helium forecast's 0.0 realized correlation argues against trusting the +5.88%.

Potential Outcomes: 1) No-news drift/chop $0.75-$1.05 into Q4 — ~45% (falsified by >$1.10 close or financing PR before Nov 20). 2) Setback, delay, or dilution disclosure → <$0.75 — ~25% (watch runway wording, ATM filings). 3) Positive readout/partner → retest $1.30-$1.80 — ~20% (falsifiable by PR terms or filing by mid-Dec). 4) Strategic interest/acquisition chatter >$2 — ~6%. 5) Macro risk-off (SPY IV term-structure steepening) drags micro-cap biotech — ~4%. Oracle: thin liquidity; only act on ask-supported quotes, e.g., 12/18 $1P at 0.15/0.30 signals the market's ~$0.75-1.00 band.

October 03, 2026